Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56α subunit-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56α subunit

Published:2016-12 Issue:12 Volume:44 Page:1156-1165.e4
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

Kawashima Ichiro,Kirito Keita

Funder

Ministry of Education, Science, Sports and Technology of Japan

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference45 articles.

1. New mutations and pathogenesis of myeloproliferative neoplasms;Vainchenker;Blood,2011

2. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med,2012

3. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis;Verstovsek;N Engl J Med,2012

4. Ruxolitinib versus standard therapy for the treatment of polycythemia vera;Vannucchi;N Engl J Med,2015

5. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis;Deininger;Blood,2015

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metformin use and risk of myeloproliferative neoplasms: a Danish population–based case-control study;Blood Advances;2024-08-27

2. Emerging Roles of B56 Phosphorylation and Binding Motif in PP2A-B56 Holoenzyme Biological Function;International Journal of Molecular Sciences;2024-03-10

3. Transcriptome analysis revealed that PME-1 suppresses inflammatory signaling, activates PI3K/Akt signaling, and promotes epithelial-mesenchymal transition;Biochemical and Biophysical Research Communications;2024-01

4. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms;Blood Cancer Journal;2023-07-10

5. Energy-Stress-Mediated AMPK Activation Promotes GPX4-Dependent Ferroptosis through the JAK2/STAT3/P53 Axis in Renal Cancer;Oxidative Medicine and Cellular Longevity;2022-10-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3